EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Co-administration of probiotics and vitamin D reduced disease severity and complications in patients with Parkinson’s disease: a randomized controlled clinical trial

Alireza Zali, Shirin Hajyani, Mehri Salari, Maryam Tajabadi-Ebrahimi, Amir M Mortazavian, Bahareh Pakpour

Psychopharmacology · 2024-09 · 241 (9) · 1905-1914

DOI: 10.1007/s00213-024-06606-9 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Psychopharmacology, online erschienen am 28.05.2024. Verfasst von Alireza Zali und 5 weiteren Autor:innen. Beteiligte Einrichtung: Functional Neurosurgery Research Center, Shohada Tajrish Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, …. Hauptthemen laut MEDLINE: Parkinson Disease, Probiotics, Severity of Illness Index, Vitamin D. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RATIONALE: Probiotics have beneficial effects on the nervous system by modulating the gut-brain axis. Additionally, vitamin D supplementation presents a potential way for ameliorating neuropsychological disorders, particularly in regions with a high prevalence of vitamin D deficiency. OBJECTIVES: The current clinical trial aimed to investigate the role of co-administered supplementation of probiotics and Vitamin D on the different inflammatory aspects of patients with Parkinson's disease. METHODS: Forty-six patients with PD were recruited From the Functional Neurosurgery Research Center, Tehran, Iran. These patients were randomly allocated to one of the two treatment groups: Group A, who received probiotic/vitamin D supplements (n = 23), and Group B who received placebo capsules (n = 23) for 12 weeks. As primary outcomes, Interferon-Gamma (IFN-γ), interleukin 1 beta (IL-1β), IL-6, IL-10, Tumor Necrosis Factor-Alpha (TNF-α), total antioxidant capacity (TAC), and malondialdehyde (MDA) in serum were evaluated at the baseline and the end of the trial. Moreover, Additional questionnaire-based factors including gastrointestinal symptom rating scale (GSRS), Beck Anxiety Inventory (BAI), and Unified Parkinson's Disease Rating Scale (UPDRS) were evaluated. RESULTS: Our findings demonstrated that the consumption of probiotic/vitamin D supplements leads to a significant decrease in IL-1β, INF-γ, IL-6, and MDA levels, while showing a significant increase in IL-10 and TAC levels compared to the placebo group (P < 0.05). Additionally, it leads to a significant decrease in the disease severity, anxiety, and gastrointestinal problems in PD patients in comparison to the placebo group (P < 0.05). CONCLUSIONS: Given the acknowledged role of inflammation in the pathogenesis of Parkinson's disease on one hand, and the recognized anti-inflammatory and antioxidant effects associated with probiotics and vitamin D on the other hand, the concurrent administration of probiotics and vitamin D supplements emerges as a promising and potentially effective treatment option for individuals with PD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseProbioticsSeverity of Illness IndexVitamin DAgedFemaleHumansMaleMiddle AgedAntioxidantsCytokinesDietary SupplementsDouble-Blind MethodIranTreatment Outcome

Stichwörter der Autor:innen

InflammationOxidative stressParkinson’s diseaseProbioticVitamin D

Substanzen

AntioxidantsCytokinesVitamin D

Autor:innen und Institutionen

  • Functional Neurosurgery Research Center, Shohada Tajrish Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Department of Biology, Faculty of Sciences, Central Tehran Branch, Islamic Azad University, P O. Box: 14155-8189, Tehran, Iran.
  • Department of Biology, Faculty of Sciences, Central Tehran Branch, Islamic Azad University, P O. Box: 14155-8189, Tehran, Iran. m.tajabadi@iauctb.ac.ir.
  • Food Safety Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Zitieren

APA

Zali, A., Hajyani, S., Salari, M., Tajabadi-Ebrahimi, M., Mortazavian, A. M., & Pakpour, B. (2024). Co-administration of probiotics and vitamin D reduced disease severity and complications in patients with Parkinson’s disease: a randomized controlled clinical trial. Psychopharmacology, 241(9), 1905-1914. https://doi.org/10.1007/s00213-024-06606-9

Vancouver

Zali A, Hajyani S, Salari M, Tajabadi-Ebrahimi M, Mortazavian AM, Pakpour B. Co-administration of probiotics and vitamin D reduced disease severity and complications in patients with Parkinson’s disease: a randomized controlled clinical trial. Psychopharmacology. 2024;241(9):1905-1914. doi:10.1007/s00213-024-06606-9

BibTeX
@article{Zali2024,
  author = {Zali, Alireza and Hajyani, Shirin and Salari, Mehri and Tajabadi-Ebrahimi, Maryam and Mortazavian, Amir M and Pakpour, Bahareh},
  title = {Co-administration of probiotics and vitamin D reduced disease severity and complications in patients with Parkinson’s disease: a randomized controlled clinical trial},
  journal = {Psychopharmacology},
  year = {2024},
  volume = {241},
  number = {9},
  pages = {1905--1914},
  doi = {10.1007/s00213-024-06606-9}
}
Kostenlos starten →